Download PDF
Semin Liver Dis 2003; 23: 047-052
DOI: 10.1055/s-2003-41634
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Implications of Peginterferon Use in Special Populations Infected with HCV

Kenneth E. Sherman
  • Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio
Further Information

Publication History

Publication Date:
21 August 2003 (online)

    Permissions and Reprints

ABSTRACT

Rapid progress in the treatment of hepatitis C virus (HCV) infection has led to highly successful therapies that lead to viral eradication and sustained viral response in more than 50% of patients. Despite these advances, certain identifiable subpopulations appear to have reduced rates of treatment response. These include patients co-infected with HCV/HIV, alcohol abusers, and African Americans infected with HCV. Using research tools including viral kinetic modeling, factor analysis, and laboratory evaluation of viral and host genomic characteristics, a number of key elements of response have been identified. Examination of special populations reveals that these groups comprise complex mixes of poor prognostic markers. These include both host and viral factors. Use of peginterferons with ribavirin improves response rates in these groups, but does not fully ameliorate the response deficit relative to patients enrolled in typical drug registration clinical trials.

KEYWORDS

HCV - treatment - HIV - alcohol - race - quasispecies - viral load

REFERENCES

  • 1 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med . 2002;  347 975-982
    CrossrefPubMedGoogle Scholar
  • 2 Manns M P, McHutchison J G, Gordon S C. et al . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet . 2001;  358 958-965
    CrossrefPubMedGoogle Scholar
  • 3 Zeuzem S, Herrmann E, Lee J H. et al . Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha-2a.  Gastroenterology . 2001;  120 1438-1447
    PubMedGoogle Scholar
  • 4 Sherman K E, Rouster S D, Chung R T, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.  Clin Infect Dis . 2002;  34 831-837
    CrossrefPubMedGoogle Scholar
  • 5 Benhamou Y, Bochet M, Di Martino V. et al . Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group.  Hepatology . 1999;  30 1054-1058
    CrossrefPubMedGoogle Scholar
  • 6 Bica I, McGovern B, Dhar R. et al . Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.  Clin Infect Dis . 2001;  32 492-497
    PubMedGoogle Scholar
  • 7 Tedaldi E M, Baker R K, Moorman A C. et al . Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.  Clin Infect Dis . 2003;  36 363-367
    CrossrefPubMedGoogle Scholar
  • 8 Goedert J J, Eyster M E, Lederman M M. et al . End-stage liver disease in persons with hemophilia and transfusion-associated infections.  Blood . 2002;  100 1584-1589
    PubMedGoogle Scholar
  • 9 Sherman K E. Diagnosis and management of the HCV/HIV-coinfected patient.  AIDS Clin Care . 2002;  14 39-48
    PubMedGoogle Scholar
  • 10 Sherman K E, Rouster S D, Horn P S. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus.  Clin Infect Dis . 2002;  35 482-487
    CrossrefPubMedGoogle Scholar
  • 11 Bonacini M, Govindarajan S, Blatt L M. et al . Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA.  J Viral Hepat . 1999;  6 203-208
    PubMedGoogle Scholar
  • 12 Ragni M V, Bontempo F A. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy.  J Infect Dis . 1999;  180 2027-2029
    CrossrefPubMedGoogle Scholar
  • 13 Chung R T, Evans S R, Yang Y. et al . Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.  AIDS . 2002;  16 1915-1923
    CrossrefPubMedGoogle Scholar
  • 14 Alter M J, Kruszon-Moran D, Nainan O V. et al . The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.  N Engl J Med . 1999;  341 556-562
    CrossrefPubMedGoogle Scholar
  • 15 Landau A, Batisse D, Van Huyen P J. et al . Efficacy and safety of combination therapy with interferon alpha-2b and ribavirin for chronic hepatitis C in HIV-infected patients.  AIDS . 2000;  14 839-844
    PubMedGoogle Scholar
  • 16 Zylberberg H, Benhamou Y, Lagneaux J L. et al . Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.  Gut . 2000;  47 694-697
    CrossrefPubMedGoogle Scholar
  • 17 Hino K, Yamaguchi Y, Fujiwara D. et al . Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study.  J Viral Hepat . 2000;  7 36-42
    CrossrefPubMedGoogle Scholar
  • 18 Pawlotsky J M, Pellerin M, Bouvier M. et al . Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.  J Med Virol . 1998;  54 256-264
    CrossrefPubMedGoogle Scholar
  • 19 Sherman K E, Andreatta C, O'Brien J. et al . Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain.  Hepatology . 1996;  23 688-694
    PubMedGoogle Scholar
  • 20 Soriano V, Garcia-Samaniego J, Bravo R. et al . Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group.  Clin Infect Dis . 1996;  23 585-591
    PubMedGoogle Scholar
  • 21 Mauss S, Klinker H, Ulmer A. et al . Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count.  Infection . 1998;  26 16-19
    PubMedGoogle Scholar
  • 22 Landau A, Batisse D, Piketty C. et al . Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients.  AIDS . 2001;  15 2149-2155
    CrossrefPubMedGoogle Scholar
  • 23 Sauleda S, Juarez A, Esteban J I. et al . Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.  Hepatology . 2001;  34 1035-1040
    CrossrefPubMedGoogle Scholar
  • 24 Chung R AJ, Alston B, Vallee, M. et al .A randomized controlled trial of pegylated interferon-alfa-2a with ribavirin versus interferon-alfa-2a with ribavirin for treatment of chronic HCV in HIV Co-infection. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 2002
    Google Scholar
  • 25 Sherman K E, Horn P, Rouster S. et al .HCV RNA kinetic response to PEG-interferon and ribavirin in HCV co-infected patients. Presented at the 9th Conference on Retrovirus and Opportunistic Infections, Seattle, WA, February 2002
    Google Scholar
  • 26 Perrone C, Carrat F, Sadr F. et al .RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated-interferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results. Presented at the XIV International Conference on AIDS, Barcelona, Spain, July 7-12, 2002
    Google Scholar
  • 27 Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.  Lancet . 2001;  357 280-281
    CrossrefPubMedGoogle Scholar
  • 28 Boxwell D FR, Sheman K E. Evidence suggesting mitochondrial toxicity in HIV/HCV co-infected patients receiving ribavirin and certain anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs). Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2003
    Google Scholar
  • 29 Mendenhall C L, Seeff L, Diehl A M. et al . Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No.  119). Hepatology . 1991;  14 581-589
    CrossrefPubMedGoogle Scholar
  • 30 Wiley T E, McCarthy M, Breidi L, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection.  Hepatology . 1998;  28 805-809
    CrossrefPubMedGoogle Scholar
  • 31 Ohnishi K, Matsuo S, Matsutani K. et al . Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers.  Am J Gastroenterol . 1996;  91 1374-1379
    PubMedGoogle Scholar
  • 32 Sherman K E, Mendenhall C, Thee D L. et al . Hepatitis C serotypes in nonalcoholic and alcoholic patients.  Dig Dis Sci . 1997;  42 2285-2291
    CrossrefPubMedGoogle Scholar
  • 33 Sherman K E, Rouster S D, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease.  Hepatology . 1999;  30 265-270
    CrossrefPubMedGoogle Scholar
  • 34 Takahashi K, Takahashi T, Takahashi S. et al . Difference in quasispecies of the hypervariable region 1 of hepatitis C virus between alcoholic and non-alcoholic patients.  J Gastroenterol Hepatol . 2001;  16 416-423
    CrossrefPubMedGoogle Scholar
  • 35 Mendenhall C L, Finkelman F, Means Jr T R. et al . Cytokine response to BCG infection in alcohol-fed mice.  Alcohol . 1999;  19 57-63
    CrossrefPubMedGoogle Scholar
  • 36 Okazaki T, Yoshihara H, Suzuki K. et al . Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers.  Scand J Gastroenterol . 1994;  29 1039-1043
    CrossrefPubMedGoogle Scholar
  • 37 Reddy K R, Hoofnagle J H, Tong M J. et al . Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.  Hepatology . 1999;  30 787-793
    CrossrefPubMedGoogle Scholar
  • 38 McHutchison J G, Poynard T, Pianko S. et al . The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C.  Gastroenterology . 2000;  119 1317-1323
    PubMedGoogle Scholar
  • 39 Keenan E, Sherman K E. Complexity and diversity of HCV RNA in African Americans.  Hepatology . 2002;  36 207A
    PubMedGoogle Scholar
  • 40 Kimball P, Elswick R K, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy.  J Med Virol . 2001;  65 510-516
    CrossrefPubMedGoogle Scholar
      >